Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Janus Kinases | 4 | 2023 | 21 | 1.300 |
Why?
|
| Interleukin-2 | 5 | 2023 | 89 | 1.290 |
Why?
|
| STAT5 Transcription Factor | 5 | 2023 | 46 | 1.240 |
Why?
|
| Signal Transduction | 7 | 2024 | 1908 | 1.140 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 16 | 1.020 |
Why?
|
| Leukemia | 1 | 2023 | 56 | 0.860 |
Why?
|
| Janus Kinase 1 | 3 | 2023 | 18 | 0.690 |
Why?
|
| Phosphorylation | 6 | 2023 | 928 | 0.530 |
Why?
|
| Cell Proliferation | 3 | 2021 | 1198 | 0.520 |
Why?
|
| Mutation | 5 | 2024 | 1095 | 0.480 |
Why?
|
| Tyrosine | 2 | 2023 | 118 | 0.440 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2013 | 6 | 0.440 |
Why?
|
| Janus Kinase 3 | 3 | 2023 | 35 | 0.420 |
Why?
|
| Cyclic AMP | 1 | 2013 | 131 | 0.420 |
Why?
|
| Cytokines | 4 | 2021 | 602 | 0.410 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 39 | 0.390 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 357 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 182 | 0.290 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2023 | 173 | 0.250 |
Why?
|
| Receptors, Interferon | 1 | 2023 | 14 | 0.230 |
Why?
|
| Janus Kinase 2 | 1 | 2023 | 32 | 0.230 |
Why?
|
| MAP Kinase Signaling System | 2 | 2021 | 169 | 0.220 |
Why?
|
| Humans | 14 | 2023 | 37093 | 0.220 |
Why?
|
| MAP Kinase Kinase 3 | 1 | 2021 | 3 | 0.200 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2021 | 6 | 0.200 |
Why?
|
| Phosphoserine | 1 | 2021 | 19 | 0.200 |
Why?
|
| Lymphoma | 2 | 2013 | 38 | 0.200 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 55 | 0.190 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 16 | 0.190 |
Why?
|
| Health Personnel | 1 | 2023 | 228 | 0.190 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 132 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 190 | 0.180 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 213 | 0.180 |
Why?
|
| Hospitalization | 1 | 2023 | 388 | 0.170 |
Why?
|
| Enzyme Activation | 3 | 2013 | 444 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2017 | 19 | 0.150 |
Why?
|
| Cell Line, Tumor | 5 | 2017 | 2231 | 0.140 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 54 | 0.140 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2016 | 10 | 0.140 |
Why?
|
| Pyridazines | 1 | 2016 | 14 | 0.140 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2017 | 70 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2021 | 239 | 0.130 |
Why?
|
| Imidazoles | 1 | 2016 | 126 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 290 | 0.130 |
Why?
|
| Mice | 2 | 2023 | 5913 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2016 | 859 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 222 | 0.120 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2013 | 9 | 0.110 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 2013 | 13 | 0.110 |
Why?
|
| Enzyme Assays | 1 | 2013 | 12 | 0.110 |
Why?
|
| Protein Subunits | 1 | 2013 | 87 | 0.110 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2013 | 73 | 0.110 |
Why?
|
| Protein Transport | 1 | 2013 | 302 | 0.100 |
Why?
|
| Animals | 3 | 2023 | 15081 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 623 | 0.100 |
Why?
|
| Monocytes | 1 | 2013 | 257 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 229 | 0.090 |
Why?
|
| Mannich Bases | 1 | 2010 | 4 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2012 | 366 | 0.090 |
Why?
|
| Gene Expression | 1 | 2013 | 674 | 0.090 |
Why?
|
| Protein Binding | 1 | 2013 | 972 | 0.090 |
Why?
|
| Hep G2 Cells | 2 | 2021 | 51 | 0.090 |
Why?
|
| Phosphotyrosine | 1 | 2021 | 23 | 0.050 |
Why?
|
| STAT Transcription Factors | 1 | 2021 | 12 | 0.050 |
Why?
|
| Antibodies | 1 | 2021 | 141 | 0.050 |
Why?
|
| Mexico | 1 | 2021 | 240 | 0.050 |
Why?
|
| Cell Survival | 2 | 2016 | 864 | 0.050 |
Why?
|
| Survival Rate | 1 | 2020 | 311 | 0.040 |
Why?
|
| Genomics | 1 | 2021 | 223 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2021 | 1180 | 0.040 |
Why?
|
| Peptides | 1 | 2021 | 320 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 739 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 974 | 0.040 |
Why?
|
| Cell Line | 1 | 2021 | 1354 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 122 | 0.040 |
Why?
|
| K562 Cells | 1 | 2016 | 32 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 18 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2017 | 113 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2016 | 46 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 177 | 0.030 |
Why?
|
| Apoptosis | 2 | 2016 | 1398 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 122 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 661 | 0.030 |
Why?
|
| Phosphoamino Acids | 1 | 2013 | 3 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 131 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 176 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 201 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2013 | 105 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 59 | 0.030 |
Why?
|
| Serine | 1 | 2012 | 75 | 0.030 |
Why?
|
| Temperature | 1 | 2013 | 286 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 448 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 234 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 626 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 601 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1039 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 807 | 0.020 |
Why?
|
| Female | 1 | 2017 | 20969 | 0.010 |
Why?
|